A high dividend yield of 7.9% makes Altria a great opportunity for income-seeking investors. Click here to read an analysis ...

allowing Altria to continue selling its products without major regulatory changes, at least in the near term. Around the same time, the Food and Drug Administration authorized 20 Zyn nicotine ...

further eroding Altria’s shares. Beyond consumer behavior, it faces mounting regulatory pressures. The U.S. Food and Drug Administration (FDA) has tightened restrictions on marketing practices.

Altria’s Profile We have a leading portfolio ... products covered by marketing granted orders from the U.S. Food and Drug Administration (FDA). Additionally, we have a majority-owned joint ...

Altria reported. Even though sales of vaping products the U.S. Food and Drug Administration has approved, like NJOY, face stiff competition from illegal devices, many of them imported from China ...

Jennifer Maloney is deputy corporate bureau chief and retail editor for The Wall Street Journal in New York. She helps oversee a team of reporters covering consumer brands, retail, manufacturing, ...

Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our ...